Gregory Renza
Stock Analyst at RBC Capital
(3.03)
# 1,238
Out of 4,479 analysts
141
Total ratings
37.12%
Success rate
1.23%
Average return
Main Sectors:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Reiterates: Outperform | $29 | $16.04 | +80.80% | 12 | Jun 25, 2024 | |
| XNCR Xencor | Maintains: Outperform | $32 → $31 | $19.02 | +62.99% | 6 | Jun 14, 2024 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $30 | $11.20 | +167.86% | 2 | Jun 14, 2024 | |
| AMGN Amgen | Maintains: Outperform | $328 → $332 | $311.01 | +6.75% | 12 | Jun 14, 2024 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $44 → $53 | $43.38 | +22.18% | 2 | Jun 4, 2024 | |
| VSTM Verastem | Maintains: Outperform | $32 → $16 | $3.25 | +392.31% | 6 | May 28, 2024 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $22 → $23 | $20.91 | +10.00% | 7 | Apr 11, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $70 | $23.14 | +202.51% | 1 | Mar 28, 2024 | |
| ADCT ADC Therapeutics | Reiterates: Outperform | $8 | $3.68 | +117.39% | 10 | Mar 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Sector Perform | $9 → $2 | $0.53 | +276.72% | 9 | Mar 14, 2024 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $14 | $6.31 | +121.87% | 1 | Mar 13, 2024 | |
| CRMD CorMedix | Maintains: Outperform | $10 → $9 | $4.28 | +110.28% | 3 | Mar 13, 2024 | |
| INO Inovio Pharmaceuticals | Reiterates: Sector Perform | $11 | $8.61 | +27.76% | 6 | Mar 7, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $53 → $45 | $28.46 | +58.12% | 6 | Mar 1, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Outperform | $195 | $106.47 | +83.15% | 7 | Feb 29, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $43 → $53 | $35.92 | +47.55% | 8 | Feb 21, 2024 | |
| EXEL Exelixis | Maintains: Outperform | $26 → $28 | $22.25 | +25.84% | 3 | Feb 7, 2024 | |
| VRDN Viridian Therapeutics | Reiterates: Outperform | $35 | $13.21 | +164.95% | 6 | Dec 14, 2023 | |
| VIRX Viracta Therapeutics | Maintains: Outperform | $7 → $6 | $0.51 | +1,076.47% | 6 | Nov 10, 2023 | |
| APTO Aptose Biosciences | Maintains: Outperform | $23 → $18 | $0.75 | +2,316.11% | 7 | Nov 10, 2023 | |
| VRCA Verrica Pharmaceuticals | Maintains: Outperform | $11 → $14 | $7.95 | +76.10% | 4 | Jul 25, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Sector Perform | $2,160 → $180 | $12.61 | +1,327.44% | 4 | Jun 27, 2023 | |
| NUVB Nuvation Bio | Maintains: Outperform | $6 → $5 | $3.16 | +58.23% | 3 | May 5, 2023 | |
| MORF Morphic Holding | Maintains: Outperform | $75 → $80 | $32.55 | +145.78% | 5 | Apr 26, 2023 | |
| APRE Aprea Therapeutics | Maintains: Sector Perform | $100 → $80 | $4.03 | +1,885.11% | 4 | Mar 16, 2022 | |
| ITRM Iterum Therapeutics | Maintains: Outperform | n/a | $1.10 | - | 1 | Dec 11, 2019 |
ACADIA Pharmaceuticals
Jun 25, 2024
Reiterates: Outperform
Price Target: $29
Current: $16.04
Upside: +80.80%
Xencor
Jun 14, 2024
Maintains: Outperform
Price Target: $32 → $31
Current: $19.02
Upside: +62.99%
Perspective Therapeutics
Jun 14, 2024
Reiterates: Outperform
Price Target: $30
Current: $11.20
Upside: +167.86%
Amgen
Jun 14, 2024
Maintains: Outperform
Price Target: $328 → $332
Current: $311.01
Upside: +6.75%
Agios Pharmaceuticals
Jun 4, 2024
Maintains: Outperform
Price Target: $44 → $53
Current: $43.38
Upside: +22.18%
Verastem
May 28, 2024
Maintains: Outperform
Price Target: $32 → $16
Current: $3.25
Upside: +392.31%
Nurix Therapeutics
Apr 11, 2024
Maintains: Outperform
Price Target: $22 → $23
Current: $20.91
Upside: +10.00%
Jasper Therapeutics
Mar 28, 2024
Initiates: Outperform
Price Target: $70
Current: $23.14
Upside: +202.51%
ADC Therapeutics
Mar 14, 2024
Reiterates: Outperform
Price Target: $8
Current: $3.68
Upside: +117.39%
Spruce Biosciences
Mar 14, 2024
Downgrades: Sector Perform
Price Target: $9 → $2
Current: $0.53
Upside: +276.72%
Fulcrum Therapeutics
Mar 13, 2024
Initiates: Outperform
Price Target: $14
Current: $6.31
Upside: +121.87%
CorMedix
Mar 13, 2024
Maintains: Outperform
Price Target: $10 → $9
Current: $4.28
Upside: +110.28%
Inovio Pharmaceuticals
Mar 7, 2024
Reiterates: Sector Perform
Price Target: $11
Current: $8.61
Upside: +27.76%
Pacira BioSciences
Mar 1, 2024
Maintains: Outperform
Price Target: $53 → $45
Current: $28.46
Upside: +58.12%
Jazz Pharmaceuticals
Feb 29, 2024
Reiterates: Outperform
Price Target: $195
Current: $106.47
Upside: +83.15%
IDEAYA Biosciences
Feb 21, 2024
Maintains: Outperform
Price Target: $43 → $53
Current: $35.92
Upside: +47.55%
Exelixis
Feb 7, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $22.25
Upside: +25.84%
Viridian Therapeutics
Dec 14, 2023
Reiterates: Outperform
Price Target: $35
Current: $13.21
Upside: +164.95%
Viracta Therapeutics
Nov 10, 2023
Maintains: Outperform
Price Target: $7 → $6
Current: $0.51
Upside: +1,076.47%
Aptose Biosciences
Nov 10, 2023
Maintains: Outperform
Price Target: $23 → $18
Current: $0.75
Upside: +2,316.11%
Verrica Pharmaceuticals
Jul 25, 2023
Maintains: Outperform
Price Target: $11 → $14
Current: $7.95
Upside: +76.10%
Avalo Therapeutics
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $12.61
Upside: +1,327.44%
Nuvation Bio
May 5, 2023
Maintains: Outperform
Price Target: $6 → $5
Current: $3.16
Upside: +58.23%
Morphic Holding
Apr 26, 2023
Maintains: Outperform
Price Target: $75 → $80
Current: $32.55
Upside: +145.78%
Aprea Therapeutics
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $4.03
Upside: +1,885.11%
Iterum Therapeutics
Dec 11, 2019
Maintains: Outperform
Price Target: n/a
Current: $1.10
Upside: -